ARQT
Price
$14.11
Change
+$0.71 (+5.30%)
Updated
Dec 19 closing price
74 days until earnings call
TSBX
Price
$0.46
Change
+$0.01 (+2.22%)
Updated
Dec 19 closing price
Ad is loading...

ARQT vs TSBX

Header iconARQT vs TSBX Comparison
Open Charts ARQT vs TSBXBanner chart's image
Arcutis Biotherapeutics
Price$14.11
Change+$0.71 (+5.30%)
Volume$2.79M
CapitalizationN/A
Turnstone Biologics
Price$0.46
Change+$0.01 (+2.22%)
Volume$61.18K
CapitalizationN/A
ARQT vs TSBX Comparison Chart
Loading...
ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TSBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARQT vs. TSBX commentary
Dec 20, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Hold and TSBX is a Hold.

COMPARISON
Comparison
Dec 20, 2024
Stock price -- (ARQT: $14.11 vs. TSBX: $0.46)
Brand notoriety: ARQT and TSBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 124% vs. TSBX: 19%
Market capitalization -- ARQT: $1.65B vs. TSBX: $10.67M
ARQT [@Biotechnology] is valued at $1.65B. TSBX’s [@Biotechnology] market capitalization is $10.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.61B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 0 FA rating(s) are green whileTSBX’s FA Score has 1 green FA rating(s).

  • ARQT’s FA Score: 0 green, 5 red.
  • TSBX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARQT and TSBX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 5 TA indicator(s) are bullish while TSBX’s TA Score has 1 bullish TA indicator(s).

  • ARQT’s TA Score: 5 bullish, 4 bearish.
  • TSBX’s TA Score: 1 bullish, 7 bearish.
According to our system of comparison, ARQT is a better buy in the short-term than TSBX.

Price Growth

ARQT (@Biotechnology) experienced а +15.18% price change this week, while TSBX (@Biotechnology) price change was -4.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.13%. For the same industry, the average monthly price growth was -2.14%, and the average quarterly price growth was +0.81%.

Reported Earning Dates

ARQT is expected to report earnings on Mar 04, 2025.

TSBX is expected to report earnings on Nov 12, 2024.

Industries' Descriptions

@Biotechnology (-4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARQT($1.65B) has a higher market cap than TSBX($10.7M). ARQT YTD gains are higher at: 336.842 vs. TSBX (-81.866). TSBX has higher annual earnings (EBITDA): -76.82M vs. ARQT (-163.28M). ARQT has more cash in the bank: 331M vs. TSBX (45.3M). TSBX has less debt than ARQT: TSBX (1.7M) vs ARQT (208M). ARQT has higher revenues than TSBX: ARQT (139M) vs TSBX (0).
ARQTTSBXARQT / TSBX
Capitalization1.65B10.7M15,430%
EBITDA-163.28M-76.82M213%
Gain YTD336.842-81.866-411%
P/E RatioN/AN/A-
Revenue139M0-
Total Cash331M45.3M731%
Total Debt208M1.7M12,242%
TECHNICAL ANALYSIS
Technical Analysis
ARQTTSBX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TSBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GEMIX23.440.25
+1.08%
Goldman Sachs Emerging Markets Eq Instl
NBHEX13.210.01
+0.08%
Neuberger Berman Equity Income E
VEXPX122.33-0.14
-0.11%
Vanguard Explorer Inv
IASCX14.28-0.04
-0.28%
Voya Small Company Port A
GABTX22.87-0.17
-0.74%
Gabelli Global Content & Connect AAA

ARQT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with SWTX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then SWTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
+5.30%
SWTX - ARQT
37%
Loosely correlated
-3.39%
BEAM - ARQT
36%
Loosely correlated
+1.51%
SANA - ARQT
35%
Loosely correlated
-5.04%
PLRX - ARQT
35%
Loosely correlated
-5.00%
BPMC - ARQT
35%
Loosely correlated
-3.11%
More

TSBX and

Correlation & Price change

A.I.dvisor tells us that TSBX and SCPX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TSBX and SCPX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TSBX
1D Price
Change %
TSBX100%
+2.56%
SCPX - TSBX
31%
Poorly correlated
+29.43%
ARQT - TSBX
26%
Poorly correlated
+5.30%
CHRS - TSBX
26%
Poorly correlated
-5.73%
PGEN - TSBX
26%
Poorly correlated
+1.84%
CDXS - TSBX
26%
Poorly correlated
-1.35%
More